Betulinic Acid for Cancer Treatment and Prevention

Betulinic acid is a natural product with a range of biological effects, for example potent antitumor activity. This anticancer property is linked to its ability to induce apoptotic cell death in cancer cells by triggering the mitochondrial pathway of apoptosis. In contrast to the cytotoxicity of betulinic acid against a variety of cancer types, normal cells and tissue are relatively resistant to betulinic acid, pointing to a therapeutic window. Compounds that exert a direct action on mitochondria present promising experimental cancer therapeutics, since they may trigger cell death under circumstances in which standard chemotherapeutics fail. Thus, mitochondrion-targeted agents such as betulinic acid hold great promise as a novel therapeutic strategy in the treatment of human cancers.

[1]  J. Pezzuto,et al.  Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  H. Majumder,et al.  Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[3]  H. Kwon,et al.  Betulinic Acid Inhibits Growth Factor‐induced in vitro Angiogenesis via the Modulation of Mitochondrial Function in Endothelial Cells , 2002, Japanese journal of cancer research : Gann.

[4]  J. Pezzuto,et al.  Pharmacokinetics and tissue distribution of betulinic acid in CD‐1 mice 1 , 1999, Biopharmaceutics & drug disposition.

[5]  G. Kroemer,et al.  Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. , 1998, Cancer research.

[6]  B. Aggarwal,et al.  Betulinic Acid Suppresses Carcinogen-Induced NF-κB Activation Through Inhibition of IκBα Kinase and p65 Phosphorylation: Abrogation of Cyclooxygenase-2 and Matrix Metalloprotease-9 , 2003, The Journal of Immunology.

[7]  I. Jeremias,et al.  Betulinic acid: a new chemotherapeutic agent in the treatment of neuroectodermal tumors , 1999, Klinische Padiatrie.

[8]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[9]  M. Sporn,et al.  Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities , 2007, Molecular Cancer Therapeutics.

[10]  J. Olsen,et al.  Structure and function of aminopeptidase N. , 2000, Advances in experimental medicine and biology.

[11]  Luyong Zhang,et al.  Synthesis and cytotoxic activity of 17-carboxylic acid modified 23-hydroxy betulinic acid ester derivatives. , 2007, Bioorganic & medicinal chemistry letters.

[12]  R. Mukherjee,et al.  Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity , 2008, Investigational New Drugs.

[13]  I. Jeremias,et al.  Betulinic acid: A new cytotoxic agent against malignant brain‐tumor cells , 1999, International journal of cancer.

[14]  S. Fulda,et al.  Sensitization for anticancer drug-induced apoptosis by betulinic Acid. , 2005, Neoplasia.

[15]  I. Jeremias,et al.  Betulinic acid-induced apoptosis in leukemia cells , 2004, Leukemia.

[16]  V. Wacheck,et al.  Betulinic acid: A new cytotoxic compound against malignant head and neck cancer cells , 2003, Head & neck.

[17]  Alexei Degterev,et al.  A decade of caspases , 2003, Oncogene.

[18]  O. Micheau.  Cellular FLICE-inhibitory protein: an attractive therapeutic target? , 2003, Expert opinion on therapeutic targets.

[19]  H. Kovacic,et al.  Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells , 2002, FEBS letters.

[20]  David E. Martin,et al.  Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection , 2007, Antimicrobial Agents and Chemotherapy.

[21]  H. Pehamberger,et al.  Betulinic Acid-induced Mcl-1 Expression in Human Melanoma — Mode of Action and Functional Significance , 2002, Molecular medicine.

[22]  P. Vandenabeele,et al.  Toxic proteins released from mitochondria in cell death , 2004, Oncogene.

[23]  M. Peter,et al.  Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. , 1997, Cancer research.

[24]  S. Ramaiah,et al.  Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. , 2007, Cancer research.

[25]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[26]  G. Evan,et al.  Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.

[27]  H. Pehamberger,et al.  Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. , 2000, The Journal of investigative dermatology.

[28]  S. Fulda,et al.  Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. , 2000, Medical and pediatric oncology.

[29]  S. Alakurtti,et al.  Pharmacological properties of the ubiquitous natural product betulin. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  P. Fischer,et al.  New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships. , 2003, Journal of medicinal chemistry.

[31]  S. Fulda,et al.  Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.

[32]  I. Jeremias,et al.  Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells , 2004, Oncogene.

[33]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[34]  J. Pezzuto,et al.  Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent , 2001, Melanoma research.

[35]  L. Galluzzi,et al.  Mitochondria as therapeutic targets for cancer chemotherapy , 2006, Oncogene.

[36]  David E. Martin,et al.  Multiple-Dose Pharmacokinetics and Safety of Bevirimat, a Novel Inhibitor of HIV Maturation, in Healthy Volunteers , 2007, Clinical pharmacokinetics.

[37]  S. Fulda,et al.  Betulinic acid as new activator of NF-κB: molecular mechanisms and implications for cancer therapy , 2005, Oncogene.

[38]  M. Peter,et al.  Activation of Mitochondria and Release of Mitochondrial Apoptogenic Factors by Betulinic Acid* , 1998, The Journal of Biological Chemistry.

[39]  N. Sawada,et al.  Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice , 2004, British Journal of Cancer.

[40]  W. El-Deiry,et al.  p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. , 2001, Experimental cell research.

[41]  J. Dichgans,et al.  Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. , 1999, The Journal of pharmacology and experimental therapeutics.

[42]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[43]  H. Koo,et al.  Development of C-20 modified betulinic acid derivatives as antitumor agents. , 2001, Bioorganic & medicinal chemistry letters.

[44]  M. Melzig,et al.  Betulinic Acid Inhibits Aminopeptidase N Activity , 1998, Planta medica.

[45]  R. Cichewicz,et al.  Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection , 2004, Medicinal research reviews.

[46]  J. Pezzuto,et al.  Betulinic acid induces apoptosis in human neuroblastoma cell lines. , 1997, European journal of cancer.

[47]  B. Aggarwal,et al.  Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. , 2003, Journal of immunology.

[48]  J. Pezzuto,et al.  Determination of betulinic acid in mouse blood, tumor and tissue homogenates by liquid chromatography-electrospray mass spectrometry. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[49]  R. Supino,et al.  Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. , 2002, Cancer letters.

[50]  Geoffrey A. Cordell,et al.  Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis , 1995, Nature Medicine.

[51]  S. Nakagawa,et al.  Sterol and triterpene derivatives from plants inhibit the effects of a tumor promoter, and sitosterol and betulinic acid inhibit tumor formation in mouse skin two-stage carcinogenesis. , 1991, Oncology.

[52]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[53]  N. Nam,et al.  Synthesis and cytotoxic activity of A-ring modified betulinic acid derivatives. , 2003, Bioorganic & medicinal chemistry letters.

[54]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[55]  M. Rieber,et al.  Induction of p53 without increase in p21WAF1 in betulinic acid-mediated cell death is preferential for human metastatic melanoma. , 1998, DNA and cell biology.